NEWS A clear commitment to high-quality, patient-centric health logistics

We are making a strategic €2 billion investment to better serve the life sciences & healthcare sector and enhance patient care. Here’s why, and how we plan to use it.

At DHL Group, we have made a strategic decision to invest €2 billion over the next five years to meet the growing and evolving needs of the life sciences and healthcare (LSH) sector. Why? For one thing, the demand is high – there is huge potential for growth – and part of our Strategy 2030 is to leverage our strong position in fast-growing sectors. Furthermore, we know that we can make a difference. Healthcare can only work if health logistics does, too. Our message is clear: we are committed to high-quality, patient-centric health logistics solutions that are global, integrated, faster, and more reliable.

By allocating this significant investment to operations worldwide, we are expanding our global LSH logistics footprint. This includes establishing new GDP-certified Pharma Hubs to handle multi-temperature shipments and integrate the health logistics strengths of our divisions. We will focus on infrastructure and technology across all logistics touchpoints – from storage, order fulfillment, and distribution to global shipping and last-mile delivery – creating even more resilient, scalable, and responsive supply chains for our customers. 

We’re witnessing a transformative shift in the LSH sector, with demand growing in many critical areas, such as clinical trials, biopharma, and cell and gene therapies. That’s why we’re also investing in more specialized cooling infrastructure for temperature-sensitive shipments as low as -196°C (cryogenic). This will increase our ability to handle everything from insulin, which needs to be refrigerated, to stem cells and some experimental mRNA vaccines, which need to be shipped at cryogenic temperatures. Cutting-edge technology will provide end-to-end visibility, ensuring product integrity, regulatory compliance, and confidence for healthcare providers and their patients.

To further enhance our capabilities and expand our services, we recently acquired CRYOPDP, a leading specialty pharma courier service. We will harness the company’s expertise to build on our Pharma Specialized Network, which is our globally integrated, end-to-end solution for specialty pharmaceuticals and clinical trials.

Our strategic investment of €2 billion through 2030 aims to boost our DHL Health Logistics brand, building our infrastructure, technology, and expertise to deliver the new and improved logistics the LSH sector needs – now and in the future.

Patients often don’t have the time to wait. We’re stepping up to help make sure they never do – to handle the complexities of healthcare supply chains at speed and get treatments to millions of people in perfect condition.